XBIT - XBiotech Inc.
IEX Last Trade
7.585
0 0%
Share volume: 41,274
Last Updated: Tue 24 Dec 2024 05:57:49 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.45%
PREVIOUS CLOSE
CHG
CHG%
$7.58
-3.22
0.74%
Fundamental analysis
9%
Profitability
0%
Dept financing
1%
Liquidity
75%
Performance
3%
Performance
5 Days
-29.02%
1 Month
-34.40%
3 Months
-33.23%
6 Months
-0.88%
1 Year
14.80%
2 Year
48.51%
Key data
Stock price
$7.58
DAY RANGE
$4.37 - $4.57
52 WEEK RANGE
$4.03 - $9.96
52 WEEK CHANGE
$14.50
DIVIDEND
$2.0995
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: John Simard
Region: US
Website: xbiotech.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: xbiotech.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
XBiotech Inc. discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis.
Recent news